Monitor for enrollment updates and future data readouts from Parts B and C, which will provide early efficacy signals. The stock may see short-term momentum on the DSMB clearance, but given the $2M market cap and historical volatility, position sizing should account for binary clinical risk.
Price Chart
Executive Summary
Clearmind Medicine announced that its independent DSMB unanimously cleared progression to Parts B and C of the Phase I/II trial for CMND-100 in Alcohol Use Disorder, following successful Part A safety data. This is a positive clinical milestone that moves the candidate into patient testing for the first time, but the company remains pre-revenue with a $2M market cap and no near-term revenue catalyst.
Key Facts
- DSMB unanimously approved advancing the Phase I/II trial to Parts B and C after Part A met its primary safety endpoint.
- Part B will evaluate CMND-100 in patients with moderate to severe AUD for the first time, in two cohorts of six patients at 80 mg and 160 mg doses.
- Part C will evaluate a fixed 160 mg daily dose over five days in healthy participants in a double-blind, placebo-controlled design.
- The trial is being conducted at Johns Hopkins University, Yale School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
- CMND-100 is a non-hallucinogenic neuroplastogen-derived oral formulation of MEAI.
Financial Impact
No financial data in filing; clinical milestone de-risks pipeline but no revenue impact near-term.
Risk Factors
- Clinical trial failure in Parts B or C could materially impair the stock.
- The company has no approved products or revenue, and may require additional dilutive financing to complete the trial.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-086120 |
| Document: ea030089802ex99-1.htm | 0001213900-26-086120 |
| Document: 0001213900-26-086120-index-headers.html | 0001213900-26-086120 |
| Document: 0001213900-26-086120-index.html | 0001213900-26-086120 |
| Document: 0001213900-26-086120.txt | 0001213900-26-086120 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | 6-K | $6.00 | awaiting T+60 | — | $5.90 (+1.67%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $5.90 (−5.30%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $5.90 (−10.61%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.90 (−10.61%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.90 (+594.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.90 (+594.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.90 (−14.04%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.90 (+525.00%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $5.90 (+472.82%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $5.90 (−408.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers